Drugs / APR-TD011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05728879 | Jan 2027 → Dec 2028 expected | primary cutaneous T-cell lymphoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05533866 | Feb 2023 → Sep 2024 | epidermolysis bullosa | Northwestern University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APR-TD011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05533866 ↗ |
| Known as | RLF-TD011 | “APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.” NCT05728879 ↗ |
| Modality | Other / unclassified | “drug/device combination product” NCT05728879 ↗ |